ACT-One proves its flexibility
This article was originally published in Clinica
Early data on Advanced Coronary Technology's ACT-One stent show that it is comparable to devices already on the market but with the advantage that it is radiopaque. A group from Toho University Hospital in Tokyo, Japan, implanted 23 ACT-One stents during a pilot study. They were successful in 90% of lesions but had to resort to using Palmaz-Schatz stents in six cases. Five stents slipped off the balloon during the study. Only three were successfully recovered.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.